Back to Search Start Over

The MPO −463G>A polymorphism and cancer risk: a meta-analysis based on 43 case–control studies.

Authors :
Chu, Haiyan
Wang, Meilin
Wang, Miaomiao
Gu, Dongying
Wu, Dongmei
Zhang, Zhizhong
Tang, Jialin
Zhang, Zhengdong
Source :
Mutagenesis; Jul2010, Vol. 25 Issue 4, p389-395, 7p, 2 Diagrams, 2 Charts, 2 Graphs
Publication Year :
2010

Abstract

Myeloperoxidase (MPO) is an endogenous oxidant enzyme that generates reactive oxygen species and plays an important role in the aetiology of cancer. The MPO −463G>A polymorphism influences MPO transcription and has been implicated in cancer risk. However, results from published studies on the association between the MPO −463G>A polymorphism and risk of cancer are conflicting. To derive a more precise estimation of association between the MPO −463G>A polymorphism and risk of cancer, we performed a meta-analysis based on 43 case–control studies, including a total of 14 171 cancer cases and 17 319 controls. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Overall, individuals with the −463A allele had a 0.93-fold lower cancer risk in a dominant model (OR = 0.93, 95% CI = 0.87–1.00). In the stratified analyses, we observed a similar association in European populations (heterozygote comparison: OR = 0.90, 95% CI = 0.82–0.99) and hospital-based studies (dominant model: OR = 0.88, 95% CI = 0.79–0.99). When stratified by cancer type, however, no significant association was found. The results suggested that the MPO −463A allele does not contribute to the development of cancer. Additional well-designed large studies are required to validate these findings in different populations. [ABSTRACT FROM PUBLISHER]

Details

Language :
English
ISSN :
02678357
Volume :
25
Issue :
4
Database :
Complementary Index
Journal :
Mutagenesis
Publication Type :
Academic Journal
Accession number :
51859886
Full Text :
https://doi.org/10.1093/mutage/geq018